Public Health Impact and Cost-Effectiveness of Adjuvanted RSVPreF3 Vaccination among Adults in the USA Aged 50–59 Years at Increased Risk of Severe RSV Disease.
Saved in:
| Title: | Public Health Impact and Cost-Effectiveness of Adjuvanted RSVPreF3 Vaccination among Adults in the USA Aged 50–59 Years at Increased Risk of Severe RSV Disease. |
|---|---|
| Authors: | Singer, David1 (AUTHOR) david.a.singer@gsk.com, La, Elizabeth M.1 (AUTHOR), Graham, Jonathan2 (AUTHOR), Molnar, Daniel3 (AUTHOR), Grace, Mei2 (AUTHOR), Poston, Sara1 (AUTHOR), Verelst, Frederik3 (AUTHOR) |
| Source: | Infectious Diseases & Therapy. Dec2025, Vol. 14 Issue 12, p2743-2761. 19p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 21938229 |
|---|---|
| DOI: | 10.1007/s40121-025-01238-8 |
